HC 5404
Alternative Names: HC-5404; HC-5404-FU; PERK inhibitor - HiberCellLatest Information Update: 11 Jun 2026
At a glance
- Originator HiberCell
- Class Alcohols; Amides; Amines; Antineoplastics; Fluorocarbons; Pyridines; Small molecules
- Mechanism of Action EIF-2 kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Gastric cancer; Renal cell carcinoma
- No development reported Breast cancer; Small cell lung cancer
Most Recent Events
- 11 Jun 2026 HC-5404 is still in phase I trial for Gastric cancer (Monotherapy, Combination therapy) in USA (HiberCell pipeline, June 2026)
- 11 Jun 2026 HC-5404 is still in phase I trial for Renal cell carcinoma (Monotherapy, Combination therapy) in USA (HiberCell pipeline, June 2026)
- 04 Jun 2026 HiberCell plans a phase Ib/II trial for Renal cell carcinoma and Gastric cancer (Combination therapy) (HiberCell pipeline, June 2026)